UK & Ireland Prostate Brachytherapy Practice Survey 2014-2016

Gemma Corey, MRCP FRCR1, A.B. Mohamed Yoosuf, MSc2, Geraldine Workman, MSc2, Monica Byrne, MSc2, Darren M. Mitchell, MD1, Suneil Jain, MD, PhD1,3

1Department of Clinical Oncology, Northern Ireland Cancer Centre, Belfast City Hospital, 2Department of Radiotherapy Medical Physics, Northern Ireland Cancer Centre, Belfast City Hospital, 3Queens University, Belfast, Antrim, Northern Ireland, UK

Abstract

Purpose: To document the current prostate brachytherapy practice across the UK and Ireland and compare with previously published audit results.

Material and methods: Participants from 25 centers attending the annual UK & Ireland Prostate Brachytherapy Conference were invited to complete an online survey. Sixty-three questions assessed the center’s experience and staffing, clinician’s experience, clinical selection criteria and scheduling, number of cases per modality in the preceding three years, low-dose-rate (LDR) pre- and post-implant technique and high-dose-rate (HDR) implant technique. Responses were collated, and descriptive statistical analysis performed.

Results: Eighteen (72%) centers responded with 17 performing LDR only, 1 performing HDR only, and 6 performing both LDR and HDR. Seventy-one percent of centers have > 10 years of LDR brachytherapy experience, whereas 71% centers that perform HDR brachytherapy have > 5 years of experience. Thirteen centers have 2 or more clinicians performing brachytherapy with 61% of lead consultants performing > 25 cases (LDR + HDR) in 2016. The number of implants (range), that includes LDR and HDR, performed by individual practitioners in 2016 was > 50 by 21%, 25-50 by 38%, and < 25 by 41%. Eight centers reported a decline in LDR monotherapy case numbers in 2016. Number of center’s performing HDR brachytherapy increased in last five years. Relative uniformity in patient selection is noted, and LDR pre- and post-implant dosimetry adheres to published quality guidelines, with an average post-implant D90 of > 145 Gy in 69% of centers in 2014 and 2015 compared to 63% in 2016. The median CT/US volume ratios were > 0.9 ≤ 1.0 (n = 4), > 1.0 ≤ 1.1 (n = 7), and > 1.1 (n = 2).

Conclusion: There is considerable prostate brachytherapy experience in the UK and Ireland. An apparent fall in LDR case numbers is noted. Maintenance of case numbers and ongoing compliance with published quality guidelines is important to sustain high quality outcomes.

Key words: LDR prostate brachytherapy, HDR prostate brachytherapy, UK & Ireland.
Sixty-three questions were grouped into six themed sections as follows:
1. Centre’s experience and staffing.
2. Consultant experience, clinical selection criteria and scheduling: number of implants per practicing consultant (banded as < 25, 25-50, and > 50), clinical selection demographics, treatment scheduling, and follow-up arrangements.
3. Number of cases treated in the preceding 3 years (banded into 0-15, 15-25, 25-50, and > 50).
4. LDR pre-implant technique: imaging/contouring, implant details, source strength, average number of seeds/needles, treatment planning (TP) objectives, and constraints.
5. LDR post-implant technique: imaging/contouring, prostate D90, room monitoring, and seed loss.
6. HDR implant technique: imaging/contouring, implant type, image registration, prescription dose, TP objectives, achieved dosimetry (V 100%), and in-vivo dosimetry.

Responses were collated, and descriptive statistical analysis performed.

**Results**

**Centre’s experience and staffing**

Eighteen (72%) of 25 invited centers responded within the timeframe. Seventeen centers perform LDR permanent seed implantation compared to 15 in 2012, and 7 centers perform HDR prostate implant compared to 3 in 2012 [13]. Six centers perform both LDR and HDR implants, as opposed to 7 in 2012, and 1 center performs HDR implantation only. Twelve (of 17) centers performing LDR brachytherapy have more than 10 years’ experience, and 5 (of 7) centers carrying out HDR implantation have more than 5 years’ experience. One center has less than 1-year HDR brachytherapy experience, whilst 2 centers have over 15 years’ experience.

The RCR’s quality assurance (QA) practice guidelines for LDR permanent seed brachytherapy recommend a minimum of 2 radiation oncologists and 2 medical physics experts (MPE) on each brachytherapy team to ‘ensure service resilience’ [6]. Table 1 shows the current reported staffing levels. Thirteen (76%) centers have 2 or more implanting consultants, and 15 (88%) centers have 2 or more medical physics experts as opposed to 25 centers in 2012 that had 2 or more clinical oncologists and MPEs [13].

**Clinical and patient selection criteria**

**Number of implants per consultant (2016)**

RCR guidelines recommend a minimum workload of 25 cases (LDR + HDR) per clinical oncologist (CO) per year [6]. As shown in Table 2, 39% of centers reported that their leading consultants performed < 25 cases in the year 2016. Similarly, 38% and 50% centers reported that their 2nd and 3rd consultants have performed < 25 cases in 2016, respectively.

**Treatment scheduling**

Twelve centers perform LDR combination therapy with 7 centers performing EBRT pre- and 5 performing EBRT post-brachytherapy. Of the 7 centers performing HDR combination therapy, 5 centers perform the HDR implant pre- and 2 centers carry out the HDR implant post-EBRT.

---

**Table 1. Brachytherapy staff numbers in UK and Ireland 2017**

| Staff member                  | No of respondents (total n = 18) | Number of staff per center (whole time equivalent) |
|-------------------------------|----------------------------------|--------------------------------------------------|
|                               |                                  | 1       | 2       | 3       | > 3    |
| Implanting consultants        | 18                               | 5       | 7       | 4       | 2      |
| Medical physics expert        | 18                               | 3       | 9       | 5       | 1      |
| Clinical scientist            | 16                               | 0       | 5       | 6       | 5      |
| Therapy radiographers         | 13                               | 2       | 2       | 5       | 4      |
| Physics trainees              | 15                               | 8       | 3       | 2       | 2      |
| Clinical trainees             | 6                                | 4       | 1       | 0       | 1      |

UK – United Kingdom

**Table 2. Number of implants (low- + high-dose-rate) performed by each consultant (2016)**

| Staff               | No of respondents (total n = 18) | Number of implants performed in the year 2016 |
|---------------------|----------------------------------|---------------------------------------------|
|                     |                                  | < 25 | > 25-50 | > 50 |
| Consultant 1        | 18                               | 7   | 7       | 4    |
| Consultant 2        | 13                               | 5   | 5       | 3    |
| Consultant 3        | 6                                | 3   | 2       | 1    |

LDR – low-dose-rate, HDR – high-dose-rate
Patient selection criteria for low-dose-rate prostate monotherapy

The responses from centers on patient selection and criteria for LDR prostate monotherapy based on various factors are reflected in Table 3. Hormonal manipulation along with LDR treatments was used in 56% of centers in selected cases for either cyto-reduction prior to implant or as an adjuvant therapy for tumor management. Current data is compared to previous published surveys.

Clinical follow-up

Clinical follow-up post-therapy is performed by oncology in 9 centers, shared care in 6 centers, and 1 center offering radiographer led follow-up alone.

Number of cases treated in 2014-2016

The number of cases treated during 2014-2016 is presented in Table 4, collected using banded groups: < 15 cases,

Table 3. Clinical selection criteria for low-dose-rate prostate monotherapy – comparison of current survey with previous American Brachytherapy Society Surveys (1998 and 2012)

| Criteria                             | Prestidge et al. [14] | Buyyounouski et al. [15] | Current study |
|--------------------------------------|-----------------------|--------------------------|--------------|
|                                      | Respondents (%)       | Respondents (%)          | Respondents (%)|
| Gleason score; number of respondents | (n = 35)              | (n = 63)                 | (n = 17)     |
| 6                                    | 12 (37)               | 17 (27)                  | –            |
| 7                                    | 12 (37)               | 40 (63)                  | 15 (88)      |
| 8                                    | 5 (14)                | 5 (8)                    | 1 (6)        |
| 9                                    | 6 (17)                | 1 (2)                    | 1 (6)        |
| Maximum T stage; number of respondents | (n = 35)              | (n = 60)                 | (n = 17)     |
| T1                                   | 2 (6)                 | 5 (8)                    | –            |
| T2                                   | 31 (88)               | 53 (89)                  | 15 (88)      |
| T3A                                  | 2 (6)                 | 2 (3)                    | 2 (12)       |
| Maximum prostate size in cc; number of respondents | (n = 35) | (n = 59) | (n = 15) |
| 30/40                                | 3 (9)/5 (14)          | –/4 (7)                  | –            |
| 50                                   | 11 (31)               | 6 (10)                   | 4 (27)       |
| 60                                   | 13 (37)               | 31 (53)                  | 7 (46)       |
| > 60                                 | 3 (9)                 | 18 (30)                  | 4 (27)       |
| Maximum PSA                          | (n = 35)              | (n = 59)                 | (n = 17)     |
| < 10                                 | 11 (31)               | 23 (39)                  | 2 (12)       |
| < 15                                 | 10 (29)               | 20 (34)                  | 8 (47)       |
| < 20                                 | 8 (23)                | 15 (25)                  | 6 (35)       |
| > 20                                 | 5 (14)                | 1 (2)                    | 1 (6)        |
| Previous TURP                        | (n = 35)              | (n = 63)                 | (n = 15)     |
| Not a contradiction/not considered   | 12 (34)               | 8 (12)                   | 5 (33)       |
| Relative contradiction              | 19 (54)               | 52 (83)                  | 6 (40)       |
| Absolute contradiction              | 4 (11)                | 3 (5)                    | 4 (27)       |
| Hormonal manipulation               | (n = 35)              | (n = 0)                  | (n = 16)     |
| Yes                                  | 94%                   | –                        | 9 (56)       |
| No                                   | –                     | –                        | 7 (44)       |

PSA – prostate specific antigen, TURP – transurethral resection of the prostate, cc – cubic centimeter
15-35 cases, 35-50 cases, 50-75 cases, and > 75 cases per year.

**Low-dose-rate pre-implant technique**

*Implant type and prescription dose*

The majority (14 of 17 centers) perform LDR brachytherapy as a ‘real-time’ implant, and 3 centers perform a ‘two-step procedure’. All 17 centers use $^{125}$I seeds, and 1 center also uses $^{103}$Pd and $^{131}$Cs. A prescription dose of 145 Gy for LDR monotherapy is used in 13 (76%) centers compared with 95% in the 2012 audit [13]. Four centers use a prescription dose of 160 Gy. For LDR combination with EBRT, the prescription dose was 110 Gy in 100% of centers in 2012. However, in 2014-2016 it is reported as: in 8 centers – 110 Gy, 2 centers – 106 Gy, 2 centers – 107 Gy, 1 center – 115 Gy, and 1 center did not specify.

*Imaging and contouring*

The most common imaging modality is ultrasound (USS), used by 65% of centers for the pre-treatment vol-

| Techniques        | Respondents (total n = 18) | No of cases treated |  < 15 | > 15–35 | > 35–50 | > 50–75 | > 75 |
|-------------------|-----------------------------|---------------------|-------|---------|---------|---------|------|
| LDR monotherapy   |                             | 2014                | 17    | 1       | 6       | 2       | 6     | 2    |
|                   |                             | 2015                | 17    | 1       | 6       | 3       | 4     | 3    |
|                   |                             | 2016                | 17    | 5       | 2       | 4       | 5     | 1    |
| LDR boost + EBRT  |                             | 2014                | 7     | –       | 6       | –       | 1     | –    |
|                   |                             | 2015                | 8     | –       | 6       | –       | 2     | –    |
|                   |                             | 2016                | 8     | –       | 8       | –       | –     | –    |
| LDR focal         |                             | 2014                | 1     | 1       | –       | –       | –     | –    |
|                   |                             | 2015                | 1     | 1       | –       | –       | –     | –    |
|                   |                             | 2016                | 1     | 1       | –       | –       | –     | –    |
| LDR salvage       |                             | 2014                | 2     | 2       | –       | –       | –     | –    |
|                   |                             | 2015                | 4     | 4       | –       | –       | –     | –    |
|                   |                             | 2016                | 5     | 5       | –       | –       | –     | –    |
| HDR boost         |                             | 2014                | 5     | 1       | –       | –       | –     | 4    |
|                   |                             | 2015                | 5     | 1       | –       | –       | –     | 4    |
|                   |                             | 2016                | 6     | 2       | –       | –       | 2     | 2    |
| HDR mono          |                             | 2014                | 4     | 3       | –       | 1       | –     | –    |
|                   |                             | 2015                | 5     | 2       | 2       | –       | 1     | –    |
|                   |                             | 2016                | 6     | 4       | 1       | –       | 1     | –    |
| HDR salvage       |                             | 2014                | 1     | 1       | –       | –       | –     | –    |
|                   |                             | 2015                | 3     | 3       | –       | –       | –     | –    |
|                   |                             | 2016                | 3     | 3       | –       | –       | –     | –    |

LDR – low-dose-rate, HDR – high-dose-rate, EBRT – external beam radiation therapy

[UK & Ireland Prostate Brachytherapy Practice Survey 2014-2016](#)
Treatment planning, seed placement, and source strength

Treatment planning (TP) is carried out by a physicist or dosimetrist in all the centers. During the implant, the ultrasound is operated by the oncologist (n = 9) or urologist (n = 9), radiologist (n = 5) or physicist (n = 1).

The majority of centers (n = 10) use stranded seed placement, 1 center uses a variation of all 4 placements including stranded, preloaded, loose, and Mick applicators. Seven centers use loose seeds for calibration, 5 use strands, and 1 center uses both. Most centers use a reference air kerma rate (RAKR) of 0.5-0.6 U (n = 12) or 0.4-0.5 U (n = 11), and 1 center uses a RAKR of > 0.7 U.

The mean number of needles used are 23 (± 5) and mean number of seeds are 72 (± 9) per LDR monotherapy implant, although this is RAKR dependent. The average number of needles and seeds per unit volume (cc) is 0.85 (± 0.5) and 1.9 (± 0.5), respectively.

Planning objectives and independent dose calculation verification

The objective for prostate V100% is ≥ 99% at 7 centers, > 98% at 2, and > 95% at 8 centers. Seven centers require a clinical target volume (CTV) V100% of > 95%. Fifteen centers report V100% to the prostate and 8 centers report V100% to a CTV. D30% to the urethra is reported by 11 centers and the majority aim for < 130% of prescribed dose. D10% is reported by 8 centers, with the majority aiming for < 150%. The majority of centers (n = 11) report a limit for D2cc rectum as < 145 Gy. A variety of constraints for prostate, CTV, urethra, and rectum were applied during treatment planning as shown in Table 5.

Post-implant dosimetry

Post-implant CT scans are routinely performed in all centers compared with 77% in 2012 [13]. Ninety-four percent (n = 16) perform the scan 4-6 weeks later, and one center on day 0/day 1. Similar to the pre-implant contouring, the oncologist performs the majority (n = 10) of the post-implant contouring followed by radiographers (n = 4), and others such as the radiologist, physicist, and dosimetrist (n = 3). Thirteen centers perform routine calculation of the CT/ultrasound volume. The median CT/US volume ratios were > 0.9 ≤ 1.0 (n = 4), > 1.0 ≤ 1.1 (n = 7), and > 1.1 (n = 2). Three centers routinely perform image registration or fusion in post-implant dosimetry, and sector analysis is performed by 4 centers.

The average prostate D90 (Gy) achieved over the period 2014-2016 is displayed in Table 6. Sixty-nine percent of the centers reported average D90 > 145 Gy in the years 2014 and 2015, whereas 63% of the centers achieved > 145 Gy in 2016.
Table 6. Post-implant average D90 for the three-year period (2014-2016)

| Year | No of respondents | < 145 Gy (85%) | > 145-155 Gy (37%) | > 155-170 Gy (37%) | > 170 Gy (13%) |
|------|------------------|----------------|------------------|-------------------|---------------|
| 2014 | 16               | 5 (31%)        | 3 (19%)          | 6 (37%)           | 2 (13%)       |
| 2015 | 16               | 5 (31%)        | 3 (19%)          | 7 (44%)           | 1 (6%)        |
| 2016 | 16               | 6 (37%)        | 2 (13%)          | 4 (25%)           | 4 (25%)       |

D90 – dose to 90% of the prostate volume, Gy – Gray

Post-procedure radiation protection room monitoring is usually performed by a nurse or physicist. Average seed loss, whereby seeds implanted were not seen on post-implant dosimetry, was < 3 per year in the majority of centers, 2 centers had seed loss > 3, but < 10 seeds per year based on number of seeds implanted versus number identified on the post-implant CT.

High-dose-rate brachytherapy technique

Of the 6 centers performing HDR monotherapy, 5 centers prescribe 19 Gy to 100% isodose volume and ensure that 95% of planning target volume (PTV) is encompassed by the 100% isodose, whereas 1 center prescribes 19 Gy to 90% of prostate volume. The definition of CTV was not acquired in this survey, although the GEC/ESTRO recommendations define CTV as the prostate capsule plus any macroscopic extracapsular disease or seminal vesicle involvement expanded by 3 mm, constrained by the anterior rectal wall and bladder base [5]. Seven centers report HDR boost doses of 15 Gy; 5 centers prescribing to 100% isodose volume and 2 centers to 90% prostate volume. Salvage therapy is performed by 4 centers, with 2 centers prescribing 15 Gy to 100% isodose volume, and the others prescribing 19 Gy to 100% isodose volume or 90% of prostate volume.

Although none of the centers performed focal therapy during the 3-year period, 1 center suggested that the prescription dose would utilize a focal boost of 21 Gy to the dominant lesion and 15 Gy to the non-dominant prostate PTV (although definition of same not provided). Details of cases numbers are detailed in Table 4.

In all but 1 center, the oncologist performs the pre-treatment contouring, with the other done by the radiologist. Ultrasound guidance is used in all centers for implants and routine QA is performed in all centers; 5 centers use metal needles and 2 use plastic needles, and most centers report an average of 15-20 needles per implant. Three centers utilize image registration (US and MRI).

The average percentage of the target volume receiving 100% of the dose (V100%) is 95-98% in 4 centers, > 95% in 1 center, and 98-100% in 2 centers. Independent dose calculation verification is carried out in all centers. One center performs in vivo dosimetry measurements using MOSFET detectors.

Comparison with 2012 RCR Prostate Brachytherapy Audit

Table 7 includes the current standards, where comparable to the standards achieved in the 2012 Audit [13].

Discussion and conclusion

Whilst the current survey had fewer responses than the RCR 2012 audit, we believe it is an accurate represe...
tation of prostate brachytherapy practice in the UK and Ireland, documenting the evolution in techniques and case numbers over the preceding 3 years. There is a clear focus on maintaining high quality implants, as evidenced by the reported D90’s and the universal use of the 3 key RCR QA markers in LDR of D90, CT/US volume ratio, and V100 across responding centers.

We note a number of centers reporting a reduction in LDR cases from 2014 to 2016 either as monotherapy or as combination therapy [1,2,3,4,5,6,7,8,9,10,13,18,19]. ASCENDE RT showed that men treated with LDR boost were twice as likely to be biochemically failure-free when compared to EBRT alone, was only presented in February 2015 at GU ASCO, and thus may not have impacted practice immediately [20]. However, it is also possible that the companion paper on toxicity could have negated the impact of this important study [21]. The continuous improvement in planning technology and review of expansion margins may help to reduce the potential of long-term urinary toxicity in combination cases, whilst hoping to maintain the biochemical benefit over EBRT alone.

The number of LDR boost treatments overall is modest. Robotic radical prostatectomies, improving convenience of hypo-fractionated EBRT for low- to intermediate-risk disease, following the CHHiP trial publication, and research interests in stereotactic radiotherapy are competing treatment options that may have impacted on referral practice [22,23,24].

HDR brachytherapy boost numbers appear to be increasing with more centers offering this modality in the last 5 years. Whilst the procedure time is longer, the radiobiological advantages, improved USS-based planning software, reduced reliance on operator skill, and potential consumable cost saving may have contributed to the limited impact of ASCENDE RT on the number of LDR boosts being performed. This cohort of high tier intermediate and high-risk cases are perhaps now directed toward HDR combined with EBRT with its own supporting evidence base [25,26].

The number of implants performed by individual consultants is noteworthy. Firstly, based on the RCR guidance, consultants are encouraged to perform at least 25 cases per year, our survey shows that 41% of implanting consultants in 2016 carried out less than this number. This may be due to the apparent fall in LDR cases reported by some centers in our survey or to an increasing number of implanting consultants individually performing fewer cases. The 2012 Audit reported that 100% of centers performed > 25 cases per year, although specific numbers per consultant was not documented but 95% of consultants performed at least 5 implants per year [12]. Secondly, the RCR guidelines suggest that in order to mentor a trainee in brachytherapy, the mentor should be performing > 100 implants over the preceding 3-year period. Our survey therefore suggests that the potential mentor cohort based on this guidance is modest. Trainees may therefore have limited exposure to brachytherapy, as has been reported in the US [26]. Reduced trainee experience and exposure to prostate brachytherapy could shrink the collegiate knowledge of patient selection and the procedure, leading to a reduced referral rate.

This survey was limited by the lower number of responses received from institutions (n = 18) than the previous 2012 RCR audit (n = 29). It is unclear if this represents failure to respond or if there has been a true reduction in the number of centers offering brachytherapy and consolidating their cases to higher volume centers. This could be answered by repeating the RCR audit using the same methodology as in 2012 and adapting our survey questionnaire. We recognize that the information gained in this survey would have been enhanced by asking for the absolute number of cases per year, their referral sources, and the specific prescription points used for the dosimetric variables, including target volume definitions and expansion margins used.

Pleasingly, our survey shows that all brachytherapy teams are continually reviewing and assessing implant quality by performing post-implant dosimetry in 100% of cases, and as an adaptive process may identify and adjust parameters for their center that maintain and improve dosimetric quality, biochemical, and toxicity outcomes.

For men with localized prostate cancer, LDR/HDR monotherapy or EBRT combined with LDR/HDR boost provides excellent biochemical outcomes [1], and several studies have reported superior outcomes, reduced toxicities, and excellent quality of life at a low-cost from either form of brachytherapy when compared to other treatments. Prostate brachytherapy offers suitable men an outstanding opportunity to achieve a high-dose, precisely targeted, and convenient treatment with excellent biochemical outcomes [2,3,7,27,28,29,30,31,32,33,34,35,36].

Acknowledgements

We gratefully acknowledge the staff from eighteen centers that responded to this survey. We also thank Right Angle Communications for assistance with survey dissemination and collection of results and to IPEM for inclusion of survey website in their Newsletter.

This work has been submitted as a summary in the IPEM Scope Magazine, United Kingdom (2017). This work has been submitted as an abstract at the ASCO-GU (American Society of Clinical Oncology – Genitourinary) Symposium (2018). This work has been submitted as an abstract at the ESTRO (European Society for Radiotherapy & Oncology) conference (2018).

Disclosure

The authors report no conflict of interest.

References

1. Zaorsky NG, Davis BJ, Nguyen PL et al. The evolution of brachytherapy for prostate cancer. Nat Rev Urol 2017; 14: 415-439.
2. Davis BJ, Horwitz EM, Lee WR et al. American Brachytherapy Society consensus guidelines for transrectual ultrasound-guided permanent prostate brachytherapy. Brachytherapy 2012; 11: 6-19.
3. Yamada Y, Rogers L, Demanes DJ et al. American Brachytherapy Society consensus guidelines for high-dose-rate prostate brachytherapy. Brachytherapy 2012; 11: 20-32.
4. Salembier C, Lavagnini P, Nickers P et al. Tumour and target volumes in permanent prostate brachytherapy: a supplement to the ESTRO/EAU/EORTC recommendations on prostate brachytherapy. Radiother Oncol 2007; 83: 3-10.

5. Hoskin PJ, Colombo A, Henry A et al. GEC/ESTRO recommendations on high dose rate afterloading brachytherapy for localised prostate cancer: an update. Radiother Oncol 2013; 107: 325-332.

6. The Royal College of Radiologists: Quality Assurance Practice guidelines for transperineal LDR permanent seed brachytherapy of prostate cancer. The Royal College of Radiologist, London 2012.

7. Zaraorsky NG, Shaijk T, Murphy CT et al. Comparison of outcomes and toxicities among radiation therapy treatment options for prostate cancer. Cancer Treat Rev 2016; 48: 50-60.

8. Hoskin PJ, Rojas AM, Bownes PJ et al. Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer. Radiother Oncol 2012; 103: 217-222.

9. Spratt DE, Soni PD, McLaughlin PW et al. American Brachytherapy Society Task Group Report: Combination of brachytherapy and external beam radiation for high-risk prostate cancer. Brachytherapy 2017; 16: 1-12.

10. Lee CD. Recent Developments and best practice in brachytherapy treatment planning. Br J Radiol 2014; 87: 20140146.

11. Peterete DG, Frank SJ, Viswanathan AN et al. Brachytherapy: where has it gone? J Clin Oncol 2015; 55: 980-982.

12. Copperberg MJ, Broering JM, Carroll PR. Time trends and local variation in primary treatment of localised prostate cancer. J Clin Oncol 2010; 28: 1117-1123.

13. Stewart AJ, Drinkwater KJ, Laing RW et al. The Royal College of Radiologists’ Audit of Prostate Brachytherapy in the Year 2012. Clin Oncol 2015; 27: 330-336.

14. Prestidge BR, Prete JJ, Buchholz TA et al. Survey of current clinical practice of permanent prostate brachytherapy in the United States. Int J Radiat Oncol Biol Phys 1998; 40: 461-465.

15. Buryyounouski MK, Davis BJ, Prestidge BR et al. A survey of current clinical practice in permanent and temporary prostate brachytherapy: 2010 Update. Brachytherapy 2012; 11: 299-305.

16. Crook J. Long-term oncologic outcomes of radical prostatectomy compared with brachytherapy-based approaches for intermediate- and high-risk prostate cancer. Brachytherapy 2015; 14: 142-147.

17. D’Amico AV, Whittington R, Malkowicz SB et al. Biochemical outcome after radical prostatectomy, external beam radiotherapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969-974.

18. Royal College of Radiologists. The role and development of brachytherapy services in the United Kingdom. Royal College of Radiologists, London 2007.

19. Zaraorsky NG, Doyle LA, Yamoah K et al. High dose rate brachytherapy boost for prostate cancer: a systematic review. Cancer Treat Rev 2014; 40: 414-425.

20. Morris WJ, Tyldeley S, Rodda S et al. Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer. Int J Radiat Oncol Biol Phys 2017; 98: 275-285.

21. Rodda S, Tyldeley S, Morris WJ et al. ASCENDE-RT: An Analysis of Treatment-Related Morbidity for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost with a Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys 2017; 98: 286-295.

22. Dearaley D, Syndikus I, Mossop H et al. Conventional versus hypofractionated high-dose-intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHIP trial. Lancet Oncol 2016; 17: 1047-1060.

23. Musunuru HB, Loblaw A. Clinical trials of stereotactic ablative radiotherapy for prostate cancer: updates and future direction. Future Oncol 2015; 11: 819-831.

24. Morton GC, Hoskin PJ. Brachytherapy: current status and future strategies - can high dose rate replace low dose rate and external beam radiotherapy? Clin Oncol 2013; 25: 474-482.

25. Morris WJ, Tyldeley S, Pai HH et al. Health-related quality of life after single-fraction high-dose-rate brachytherapy and hypofractionated external beam radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2011; 80: 1299-1305.

26. Orio PF 3rd, Nguyen PL, Buzurovic I et al. Prostate Brachytherapy Case Volumes by Academic and Nonacademic Practices: Implications for Future Residency Training. Int J Radiat Oncol Biol Phys 2016; 96: 624-628.

27. Shen X, Keith SW, Mishra MV et al. The impact of brachytherapy on prostate cancer-specific mortality for definitive radiation therapy of high-grade prostate cancer: a population-based analysis. Int J Radiat Oncol Biol Phys 2012; 83: 1154-1159.

28. Hoskin P, Rojas A, Ostler P et al. High-dose-rate brachytherapy with or without supplemental external beam radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2011; 81: 1286-1292.

29. Bice WS, Prestidge BR, Kurtzman SM et al. Recommendations for permanent prostate brachytherapy with 131I-cs: a consensus report from the Cesium Advisory Group. Brachytherapy 2008; 7: 290-296.

30. DeMaris D J, Martinez AA, Ghilezan M et al. High-dose-rate monotherapy: safe and effective brachytherapy for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys 2011; 81: 1376-1384.

31. Grimm P, Billett I, Bostwick D et al. Comparative analysis of prostate specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treated by medical therapy. Results from the Prostate Cancer Research Study Group. BJU Int 2012; 109 Suppl 1: 22-29.

32. Dearnaley D, Syndikus I, Mossop H et al. Conventional versus hypofractionated high-dose-intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHIP trial. Lancet Oncol 2016; 17: 1047-1060.

33. Musunuru HB, Loblaw A. Clinical trials of stereotactic ablative radiotherapy for prostate cancer: updates and future direction. Future Oncol 2015; 11: 819-831.

34. Montgomery GC, Loblaw DA, Chung H et al. Health-related quality of life after single-fraction high-dose-rate brachytherapy and hypofractionated external beam radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2011; 80: 1299-1305.

35. Orio PF 3rd, Nguyen PL, Buzurovic I et al. Prostate Brachytherapy Case Volumes by Academic and Nonacademic Practices: Implications for Future Residency Training. Int J Radiat Oncol Biol Phys 2016; 96: 624-628.

36. DeMaris D J, Martinez AA, Ghilezan M et al. High-dose-rate monotherapy: safe and effective brachytherapy for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys 2011; 81: 1286-1292.

37. Ghadjar P, Keller T, Rentsch CA et al. Toxicity and early treatment outcomes in low- and intermediate-risk prostate cancer managed by high-dose-rate brachytherapy as a monotherapy. Brachytherapy 2009; 8: 45-51.

38. Hoskin P, Rojas A, Lowe G et al. High-dose-rate brachytherapy alone for localized prostate cancer in patients at moderate or high risk of biochemical recurrence. Int J Radiat Oncol Biol Phys 2012; 82: 1376-1384.

39. Grimm P, Billett I, Bostwick D et al. Comparative analysis of prostate specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treated by medical therapy. Results from the Prostate Cancer Research Study Group. BJU Int 2012; 109 Suppl 1: 22-29.

40. Dearnaley D, Syndikus I, Mossop H et al. Conventional versus hypofractionated high-dose-intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHIP trial. Lancet Oncol 2016; 17: 1047-1060.

41. Musunuru HB, Loblaw A. Clinical trials of stereotactic ablative radiotherapy for prostate cancer: updates and future direction. Future Oncol 2015; 11: 819-831.

42. Montgomery GC, Loblaw DA, Chung H et al. Health-related quality of life after single-fraction high-dose-rate brachytherapy and hypofractionated external beam radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2011; 80: 1299-1305.